Ottawa, Ontario (PRWEB) January 29, 2013
Spartan Bioscience today announced a distribution agreement with Medial for the Spartan RX—the first point-of-care DNA test in medicine.(1) Medial is a leading provider of medical devices to hospitals in the Czech Republic.
The Spartan RX point-of-care DNA testing system identifies carriers of CYP2C19 loss-of-function mutations, which are carried by approximately 30% of the world’s population.(2) Genetic carriers who receive Plavix® (clopidogrel) following a cardiac stent have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) In 2009, Plavix® was the second best-selling drug in the world, with over $9 billion in revenues.
“Medial has over 20 years of experience in bringing innovative medical devices to the Czech Republic,” said Paul Lem, M.D., CEO of Spartan Bioscience. “We are pleased that Medial will now oversee distribution of the Spartan RX in the Czech market.”
“We have already received significant interest in the Spartan RX from many cardiologists,” said Jan Marek, General Manager of Medial. “We look forward to a long and profitable partnership with Spartan Bioscience.”
About the Spartan RX CYP2C19
The Spartan RX CYP2C19 is the first bedside DNA test in medicine.(1) It identifies carriers of CYP2C19 genetic mutations in 1 hour. These mutations are carried by approximately 30 percent of the world’s population.(2) Genetic carriers who receive Plavix® following a cardiac stent insertion to open clogged arteries have a 42 percent higher risk of death, stroke, or heart attack in the first year compared to non-carriers.(3) Currently, genetic testing is performed in central labs and it takes up to seven days to get a test result back. A rapid test is needed because most of the complications for CYP2C19
Copyright©2012 Vocus, Inc.
All rights reserved